Atherogenic lipids and endothelial dysfunction: Mechanisms in the genesis of ischemic syndromes

被引:46
作者
Adams, MR [1 ]
Kinlay, S [1 ]
Blake, GJ [1 ]
Orford, JL [1 ]
Ganz, P [1 ]
Selwyn, AP [1 ]
机构
[1] Brigham & Womens Hosp, Dept Cardiol, Boston, MA 02115 USA
来源
ANNUAL REVIEW OF MEDICINE | 2000年 / 51卷
关键词
endothelium; nitric oxide; cholesterol; atherosclerosis;
D O I
10.1146/annurev.med.51.1.149
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Atherogenic lipids, particularly oxidized low-density lipoprotein, are responsible for a wide range of cellular dysfunctions within the vessel wall. The effects on endothelial cells disrupt normal control of vasomotion, with a reduction of effective nitric oxide activity, the development of a procoagulant surface, chronic low-grade inflammation, and abnormal cell growth. These changes are central not only in the development of atherosclerosis but also in the evolution of both stable and unstable ischemic syndromes. There is growing evidence that these abnormal changes in cell function respond rapidly to changes in the atherogenic lipids. Certain cell functions can improve within hours or days of cholesterol lowering.
引用
收藏
页码:149 / 167
页数:19
相关论文
共 112 条
[81]   VASCULAR ENDOTHELIAL-CELLS SYNTHESIZE NITRIC-OXIDE FROM L-ARGININE [J].
PALMER, RMJ ;
ASHTON, DS ;
MONCADA, S .
NATURE, 1988, 333 (6174) :664-666
[82]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[83]   NATIVE LOW-DENSITY-LIPOPROTEIN INCREASES ENDOTHELIAL-CELL NITRIC-OXIDE SYNTHASE GENERATION OF SUPEROXIDE ANION [J].
PRITCHARD, KA ;
GROSZEK, L ;
SMALLEY, DM ;
SESSA, WC ;
WU, MD ;
VILLALON, P ;
WOLIN, MS ;
STEMERMAN, MB .
CIRCULATION RESEARCH, 1995, 77 (03) :510-518
[84]   COMPARATIVE PHARMACOLOGY OF ENDOTHELIUM-DERIVED RELAXING FACTOR, NITRIC-OXIDE AND PROSTACYCLIN IN PLATELETS [J].
RADOMSKI, MW ;
PALMER, RMJ ;
MONCADA, S .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 92 (01) :181-187
[85]   In vivo low density lipoprotein oxidation relates to coronary reactivity in young men [J].
Raitakari, OT ;
Pitkanen, OP ;
Lehtimaki, T ;
Lahdenpera, S ;
Iida, H ;
YlaHerttuala, S ;
Luoma, J ;
Mattila, K ;
Nikkari, T ;
Taskinen, MR ;
Viikari, JSA ;
Knuuti, J .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (01) :97-102
[86]   Increased formation of distinct F2 isoprostanes in hypercholesterolemia [J].
Reilly, MP ;
Praticó, D ;
Delanty, N ;
DiMinno, G ;
Tremoli, E ;
Rader, D ;
Kapoor, S ;
Rokach, J ;
Lawson, J ;
FitzGerald, GA .
CIRCULATION, 1998, 98 (25) :2822-2828
[87]   THE PATHOGENESIS OF ATHEROSCLEROSIS - A PERSPECTIVE FOR THE 1990S [J].
ROSS, R .
NATURE, 1993, 362 (6423) :801-809
[88]  
RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, P1
[89]   The atherogenic lipoprotein phenotype and vascular endothelial dysfunction [J].
Sattar, N ;
Petrie, JR ;
Jaap, AJ .
ATHEROSCLEROSIS, 1998, 138 (02) :229-235
[90]   Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation [J].
Schachinger, V ;
Halle, M ;
Minners, J ;
Berg, A ;
Zeiher, AM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (04) :927-934